Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid

CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(03): 185-188
DOI: 10.4103/sajc.sajc_87_19

Letter to the Editor

Autor*innen

Sachin Dhumal

Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra
Arun Chandrasekharan

Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra
Vijay Patil

Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra
Vanita Noronha

Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra
Amit Joshi

Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra
Ameya Puranik

Department of Nuclear Medicine, Tata Memorial Centre, HBNI, Mumbai, Maharashtra
Venkatesh Rangarajan

Department of Nuclear Medicine, Tata Memorial Centre, HBNI, Mumbai, Maharashtra
Kumar Prabhash

Department of Nuclear Medicine, Tata Memorial Centre, HBNI, Mumbai, Maharashtra

References
1 Stenner M, Klussmann JP. Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved. Eur Arch Otorhinolaryngol 2009;266:333-41.
2 Wang X, Luo Y, Li M, Yan H, Sun M, Fan T, et al. Management of salivary gland carcinomas – A review. Oncotarget 2017;8:3946-56.
3 Patil VM, Prabhash K, Noronha V, Joshi A, Muddu V, Dhumal S, et al. Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers. Oral Oncol 2014;50:1000-4.
4 Ho K, Lin H, Ann DK, Chu PG, Yen Y. An overview of the rare parotid gland cancer. Head Neck Oncol 2011;3:40.
5 Licitra L, Cavina R, Grandi C, Palma SD, Guzzo M, Demicheli R, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 1996;7:640-2.